Literature DB >> 28829727

Ferroquine Advances.

David L Saunders1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28829727      PMCID： PMC5544105          DOI： 10.4269/ajtmh.17-0373

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN： 0002-9637            Impact factor:   2.345


× No keyword cloud information.
  6 in total

1.  Piperaquine Population Pharmacokinetics and Cardiac Safety in Cambodia.

Authors:  Pattaraporn Vanachayangkul; Chanthap Lon; Michele Spring; Sommethy Sok; Winita Ta-Aksorn; Chanikarn Kodchakorn; Sut-Thang Pann; Soklyda Chann; Mali Ittiverakul; Sabaithip Sriwichai; Nillawan Buathong; Worachet Kuntawunginn; Mary So; Theng Youdaline; Erin Milner; Mariusz Wojnarski; Charlotte Lanteri; Jessica Manning; Satharath Prom; Mark Haigney; Louis Cantilena; David Saunders
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

2.  Dihydroartemisinin-piperaquine failure in Cambodia.

Authors:  David L Saunders; Pattaraporn Vanachayangkul; Chanthap Lon
Journal:  N Engl J Med       Date:  2014-07-31       Impact factor: 91.245

3.  Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria.

Authors:  Susan A Charman; Sarah Arbe-Barnes; Ian C Bathurst; Reto Brun; Michael Campbell; William N Charman; Francis C K Chiu; Jacques Chollet; J Carl Craft; Darren J Creek; Yuxiang Dong; Hugues Matile; Melanie Maurer; Julia Morizzi; Tien Nguyen; Petros Papastogiannidis; Christian Scheurer; David M Shackleford; Kamaraj Sriraghavan; Lukas Stingelin; Yuanqing Tang; Heinrich Urwyler; Xiaofang Wang; Karen L White; Sergio Wittlin; Lin Zhou; Jonathan L Vennerstrom
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-07       Impact factor: 11.205

4.  A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.

Authors:  F Joel Leong; Ruobing Li; Jay Prakash Jain; Gilbert Lefèvre; Baldur Magnusson; Thierry T Diagana; Peter Pertel
Journal:  Antimicrob Agents Chemother       Date:  2014-08-11       Impact factor: 5.191

Review 5.  New developments in anti-malarial target candidate and product profiles.

Authors:  Jeremy N Burrows; Stephan Duparc; Winston E Gutteridge; Rob Hooft van Huijsduijnen; Wiweka Kaszubska; Fiona Macintyre; Sébastien Mazzuri; Jörg J Möhrle; Timothy N C Wells
Journal:  Malar J       Date:  2017-01-13       Impact factor: 2.979

6.  Efficacy of two versus three-day regimens of dihydroartemisinin-piperaquine for uncomplicated malaria in military personnel in northern Cambodia: an open-label randomized trial.

Authors:  Chanthap Lon; Jessica E Manning; Pattaraporn Vanachayangkul; Mary So; Darapiseth Sea; Youry Se; Panita Gosi; Charlotte Lanteri; Suwanna Chaorattanakawee; Sabaithip Sriwichai; Soklyda Chann; Worachet Kuntawunginn; Nillawan Buathong; Samon Nou; Douglas S Walsh; Stuart D Tyner; Jonathan J Juliano; Jessica Lin; Michele Spring; Delia Bethell; Jaranit Kaewkungwal; Douglas Tang; Char Meng Chuor; Prom Satharath; David Saunders
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.